PACS Group, Inc. PACS R2K
Healthcare · Medical Care Facilities · United States
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. It also provides senior care and independent living facilities. The company engages in the acquisition, ownership, and leasing of health care-related properties. PACS Group, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
READ MORE ›$36.65
+269.46% 1Y
Market & Price
Market Cap
$5.80B
Current Price
$36.65
High / Low (52W)
$42.13 / $7.71
Beta
-0.03
Valuation
Stock P/E
23.65
Industry PE
23.65
Forward P/E
14.60
PEG Ratio
1.08
Book Value
$6.60
Price to Book
5.55
P/S
1.07
EV/EBITDA
20.48
Dividend Yield
-
Profitability & Returns
ROCE
6.83%
ROE
27.11%
ROA
4.27%
Profit Margin
4.49%
Op Margin
8.45%
EPS (Latest Qtr)
$0.50
EPS (TTM)
$1.55
Balance Sheet & Liquidity
Debt/Equity
3.36
Quick Ratio
0.91
Current Ratio
0.99
Debt
$3.51B
Total Assets
$5.58B
Current Assets
$1.07B
Working Capital
$68.31M
Ownership
Promoter Holding
70.22%
Chg in Prom Hold
-
FII / Inst Holding
30.37%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$9.06B
Total Revenue (TTM)
$5.43B
EBITDA
$442.52M
Free Cash Flow
$303.31M
Operating Cash Flow
$490.32M
Shares Outstanding
158.27M
Gross Margin
16.77%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
29.74%
Profit 5Y
8.37%
Revenue (YoY)
11.20%
Earnings (YoY)
194.10%
PROS
- Strong return on equity of 27.1%.
- Compounding revenue at 29.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PACS PACS Group, Inc. R2K | 36.65 | 23.65 | $5.80B | - | 6.83% | 27.11% | 29.74% | 8.37% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 707.83M | 760.42M | 788.93M | 919.41M | 935.26M | - | - | 1.28B | 1.31B | 1.34B | 1.36B | 1.42B |
| Cost of Revenue | - | - | - | - | - | - | - | 1.12B | 1.12B | 1.14B | 1.13B | 1.17B |
| Gross Profit | - | - | - | - | - | - | - | 159.56M | 194.01M | 203.20M | 223.56M | 250.43M |
| Operating Expenses | - | - | - | - | - | - | - | 111.42M | 113.51M | 116.93M | 128.87M | 130.39M |
| Operating Income | 59.30M | 49.54M | 36.40M | 65.31M | -37.18M | - | - | 48.14M | 80.50M | 86.27M | 94.69M | 120.03M |
| EBITDA | - | - | - | - | - | - | - | 62.34M | 96.14M | 99.23M | 110.77M | 138.24M |
| Interest Expense | - | - | - | - | - | - | - | 6.90M | 4.35M | 8.53M | 8.58M | 6.42M |
| Pretax Income | - | - | - | - | - | - | - | 42.73M | 78.61M | 76.30M | 86.81M | 113.74M |
| Tax Provision | - | - | - | - | - | - | - | 14.35M | 27.65M | 23.97M | 27.03M | 33.07M |
| Net Income | 37.60M | 21.22M | 19.93M | 34.82M | -31.88M | - | - | 28.47M | 50.96M | 52.41M | 59.70M | 80.69M |
| Diluted EPS | 0.29 | 0.16 | 0.15 | 0.27 | -0.21 | 0.10 | - | 0.17 | 0.31 | 0.32 | - | 0.50 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 2.42B | 3.11B | 4.09B | 5.29B |
| Cost of Revenue | 2.02B | 2.66B | 3.58B | 4.51B |
| Gross Profit | 400.68M | 447.07M | 507.69M | 780.33M |
| Operating Expenses | 171.32M | 239.30M | 384.62M | 470.73M |
| Operating Income | 229.36M | 207.77M | 123.07M | 309.60M |
| EBITDA | 254.89M | 232.87M | 186.70M | 368.48M |
| Interest Expense | 25.54M | 49.92M | 44.34M | 28.36M |
| Pretax Income | 207.04M | 157.32M | 101.55M | 284.45M |
| Tax Provision | 56.55M | 44.44M | 46.21M | 92.99M |
| Net Income | 150.50M | 112.87M | 55.76M | 191.54M |
| Diluted EPS | 1.00 | 0.76 | 0.38 | 1.22 |
Compounded Sales Growth
| 5 Years: | 29.74% |
| 1 Year: | 11.20% |
Compounded Profit Growth
| 5 Years: | 8.37% |
| 1 Year: | 194.10% |
Stock Price Performance
| 1 Year: | +269.46% |
| 6 Months: | +15.32% |
| 3 Months: | +0.38% |
| 1 Month: | +9.73% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.46B | 3.51B | 3.86B | 3.93B | 5.24B | 5.58B |
| Current Assets | - | 511.16M | 722.15M | - | - | 938.26M | 1.07B |
| Cash & Equivalents | - | 58.27M | 73.42M | 81.21M | 73.37M | 157.67M | 197.02M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | 370.92M | 547.81M | - | - | 641.77M | 628.13M |
| Total Liabilities | - | 2.39B | 3.41B | 3.74B | 3.39B | 4.53B | 4.63B |
| Current Liabilities | - | 483.86M | 456.93M | 535.38M | 488.20M | 978.43M | 1.00B |
| Long Term Debt | - | 438.34M | 715.71M | - | - | 250.98M | 344.80M |
| Total Debt | - | 1.93B | 2.80B | - | - | 3.50B | 3.47B |
| Total Equity | -24.81M | 63.65M | 96.13M | 113.67M | 536.84M | 709.55M | 946.77M |
| Shares Outstanding | - | 147.77M | 147.77M | - | - | 155.18M | 156.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 92.61M | 63.70M | 367.34M | 404.22M |
| Investing Cash Flow | - | -75.32M | -172.79M | -442.68M | -264.02M |
| Financing Cash Flow | - | 12.35M | 129.59M | 117.48M | -68.99M |
| Capital Expenditure | - | -78.24M | -172.81M | -349.81M | -249.16M |
| Free Cash Flow | - | 14.38M | -109.11M | 17.53M | 155.07M |
| Net Change in Cash | - | 29.64M | 20.50M | 42.14M | 71.21M |
| Dividends Paid | - | 60.28M | 80.39M | 33.72M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 16.5% | 14.4% | 12.4% | 14.8% |
| Operating Margin % | 9.5% | 6.7% | 3.0% | 5.9% |
| Net Margin % | 6.2% | 3.6% | 1.4% | 3.6% |
| ROE % | 236.5% | 117.4% | 7.9% | 20.2% |
| ROCE % | 11.6% | 6.8% | 2.9% | 6.8% |
Shareholding Pattern
Insiders
70.22%
Institutions
30.37%
Public Float
101.99%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cohen & Steers Inc. | 5.76% | 9.12M | $334.36M |
| 2 | FMR, LLC | 3.32% | 5.25M | $192.34M |
| 3 | Blackrock Inc. | 2.39% | 3.78M | $138.36M |
| 4 | Alyeska Investment Group, L.p. | 1.90% | 3.00M | $110.05M |
| 5 | Crewe Advisors LLC | 1.74% | 2.75M | $100.94M |
| 6 | Vanguard Portfolio Management LLC | 1.18% | 1.86M | $68.21M |
| 7 | Vanguard Capital Management LLC | 1.14% | 1.80M | $66.14M |
| 8 | American Century Companies Inc | 1.14% | 1.81M | $66.32M |
| 9 | Ameriprise Financial, Inc. | 0.71% | 1.12M | $41.10M |
| 10 | Geode Capital Management, LLC | 0.70% | 1.11M | $40.82M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PACS
No recent headlines available.